Quoix E, Audigier-Valette C, Lavolé A, et al. - Researchers compared maintenance with either pemetrexed (500 mg/m ² d1, 22) in patients with non–squamous cell carcinoma or gemcitabine (1,150 mg/m ² d1, 8, 22) in squamous cell carcinoma vs simple observation in elderly (aged 70–89 years) patients suffering from advanced non–small cell lung carcinoma (NSCLC) with neither EGFR mutation nor ALK rearrangement who had not progressed following four cycles of monthly carboplatin and weekly paclitaxel. Eligibility criteria for inclusion in this randomised trial were performance status 0–2, mini-mental score > 23, and creatinine clearance ≥ 45 mL/min. Overall survival (OS) was the primary endpoint. From May 2013 to October 2016, they enrolled 643 patients. Findings demonstrated that a significantly longer progression-free survival, but not OS, was afforded by switch maintenance therapy. Therefore, it should not be proposed to elderly patients suffering from advanced NSCLC.